23-year trends of antimicrobial resistance in Salmonella Paratyphi A indicates low rates on resistance acquisition

Background: Typhoid and paratyphoid remain common bloodstream infections in areas with suboptimal water and sanitation infrastructure. Paratyphoid, caused by Salmonella Paratyphi A, is less prevalent than typhoid and its antimicrobial resistance (AMR) trends are less documented. Empirical treatment for paratyphoid is commonly based on the knowledge of susceptibility of Salmonella Typhi, which causes typhoid. Hence, with rising drug resistance in Salmonella Typhi, last-line antibiotics like ceftriaxone and azithromycin are prescribed for both typhoid and paratyphoid. Here, we report 23-year AMR trends of Salmonella Paratyphi A in Bangladesh. Methods: From 1999 to 2021, we conducted enteric fever surveillance in two major pediatric hospitals and three clinics in Dhaka, Bangladesh. Blood cultures were performed at the discretion of the treating physicians; cases were confirmed by culture, serological and biochemical tests. Antimicrobial susceptibility was determined following CLSI guidelines. Results: Over 23 years, we identified 2,725 blood culture-confirmed paratyphoid cases. Over 97% of the isolates were susceptible to ampicillin, chloramphenicol, and cotrimoxazole, and no isolate was resistant to all three. No resistance to ceftriaxone was recorded, and >99% of the isolates were sensitive to azithromycin. A slight increase in minimum inhibitory concentration (MIC) is noticed for ceftriaxone but current average MIC is 32-fold lower than the resistance cut-off. Over 99%, of the isolates exhibited decreased susceptibility to ciprofloxacin. Conclusions: Salmonella Paratyphi A has remained susceptible to most antibiotics, unlike Salmonella Typhi, despite widespread usage of many antibiotics in Bangladesh. The data can guide evidence-based policy decisions for empirical treatment of paratyphoid fever.

[1]  M. Carey Gateway to Typhoid Conjugate Vaccine Introduction in India and Beyond—Programmatic Effectiveness of a Public Sector Typhoid Conjugate Vaccine Campaign in Navi Mumbai , 2023, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  G. Dougan,et al.  Paratype: a genotyping tool for Salmonella Paratyphi A reveals its global genomic diversity , 2022, Nature communications.

[3]  J. Andrews,et al.  Programmatic Effectiveness of a Pediatric Typhoid Conjugate Vaccine Campaign in Navi Mumbai, India , 2022, medRxiv.

[4]  I. Bogoch,et al.  Incidence of typhoid and paratyphoid fever in Bangladesh, Nepal, and Pakistan: results of the Surveillance for Enteric Fever in Asia Project , 2022, The Lancet. Global health.

[5]  I. Bogoch,et al.  Estimating typhoid incidence from community-based serosurveys: a multicohort study , 2022, The Lancet. Microbe.

[6]  G. Kang,et al.  Evaluation of Antimicrobial Susceptibility Profile in Salmonella Typhi and Salmonella Paratyphi A: Presenting the Current Scenario in India and Strategy for Future Management , 2021, The Journal of infectious diseases.

[7]  S. Saha,et al.  Invasive Bacterial Vaccine-Preventable Disease Surveillance: Successes and Lessons Learned in Bangladesh for a Sustainable Path Forward , 2021, The Journal of infectious diseases.

[8]  C. Jenkins,et al.  Phylogenomics and antimicrobial resistance of Salmonella Typhi and Paratyphi A, B and C in England, 2016–2019 , 2021, Microbial genomics.

[9]  K. Neuzil,et al.  Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial , 2021, The Lancet.

[10]  N. Bar-Zeev,et al.  Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study , 2021, The Lancet. Global health.

[11]  M. Shoaib,et al.  Disc Diffusion Testing of Azithromycin Against Clinical Isolates of Typhoidal Salmonellae: A Diagnostic Conundrum , 2021, Cureus.

[12]  C. Parry,et al.  Azithromycin susceptibility testing of Salmonella enterica serovar Typhi: Impact on management of enteric fever , 2021, Clinical Infection in Practice.

[13]  J. Andrews,et al.  Tracking the Emergence of Azithromycin Resistance in Multiple Genotypes of Typhoidal Salmonella , 2021, mBio.

[14]  Gemma C. Langridge,et al.  Genomic surveillance detects Salmonella enterica serovar Paratyphi A harbouring blaCTX-M-15 from a traveller returning from Bangladesh , 2020, PloS one.

[15]  S. Baker,et al.  Efficacy of Typhoid Conjugate Vaccine in Nepal: An Interim Analysis of a Participant-and Observer-Blinded Randomized Phase III Trial , 2019, The New England journal of medicine.

[16]  Ayenew Molla Lakew,et al.  The global burden of non-typhoidal salmonella invasive disease: a systematic analysis for the Global Burden of Disease Study 2017 , 2019, The Lancet. Infectious diseases.

[17]  J. Andrews,et al.  Molecular mechanism of azithromycin resistance among typhoidal Salmonella strains in Bangladesh identified through passive pediatric surveillance , 2019, PLoS neglected tropical diseases.

[18]  J. Andrews,et al.  Epidemiology of Typhoid and Paratyphoid: Implications for Vaccine Policy , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  S. Baker,et al.  Multidrug resistant enteric fever in South Asia: unmet medical needs and opportunities , 2019, British Medical Journal.

[20]  I. Bogoch,et al.  Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance. , 2019, The Lancet. Infectious diseases.

[21]  R. Adhikary,et al.  Trends in antibiotic susceptibility of enteric fever isolates from South India, 2002-2013. , 2019, Medical journal, Armed Forces India.

[22]  Tetsuya Matsumoto,et al.  Characteristics of Resistance Mechanisms and Molecular Epidemiology of Fluoroquinolone-Nonsusceptible Salmonella enterica Serovar Typhi and Paratyphi A Isolates from a Tertiary Hospital in Dhaka, Bangladesh. , 2018, Microbial drug resistance.

[23]  S. Saha,et al.  Designing Comprehensive Public Health Surveillance for Enteric Fever in Endemic Countries: Importance of Including Different Healthcare Facilities , 2018, The Journal of infectious diseases.

[24]  T. Burki Typhoid conjugate vaccine gets WHO prequalification. , 2018, The Lancet. Infectious diseases.

[25]  David R Murdoch,et al.  Laboratory and molecular surveillance of paediatric typhoidal Salmonella in Nepal: Antimicrobial resistance and implications for vaccine policy , 2018, bioRxiv.

[26]  Priyanka Sharma,et al.  Changing trends of culture-positive typhoid fever and antimicrobial susceptibility in a tertiary care North Indian Hospital over the last decade , 2018, Indian journal of medical microbiology.

[27]  S. Baker,et al.  A 23-year retrospective investigation of Salmonella Typhi and Salmonella Paratyphi isolated in a tertiary Kathmandu hospital , 2017, PLoS neglected tropical diseases.

[28]  R. Black,et al.  Integration of enteric fever surveillance into the WHO-coordinated Invasive Bacterial-Vaccine Preventable Diseases (IB-VPD) platform: A low cost approach to track an increasingly important disease , 2017, PLoS neglected tropical diseases.

[29]  P. Khanal,et al.  Renaissance of Conventional First-Line Antibiotics in Salmonella enterica Clinical Isolates: Assessment of MICs for Therapeutic Antimicrobials in Enteric Fever Cases from Nepal , 2017, BioMed research international.

[30]  D. Ahmed,et al.  Bacterial etiology of bloodstream infections and antimicrobial resistance in Dhaka, Bangladesh, 2005–2014 , 2017, Antimicrobial Resistance & Infection Control.

[31]  F. Weill,et al.  Genomic analysis of Salmonella enterica serotype Paratyphi A during an outbreak in Cambodia, 2013–2015 , 2016, Microbial genomics.

[32]  V. Mogasale,et al.  What proportion of Salmonella Typhi cases are detected by blood culture? A systematic literature review , 2016, Annals of Clinical Microbiology and Antimicrobials.

[33]  S. Dutta,et al.  Antimicrobial Resistance, Virulence Profiles and Molecular Subtypes of Salmonella enterica Serovars Typhi and Paratyphi A Blood Isolates from Kolkata, India during 2009-2013 , 2014, PloS one.

[34]  M. Forouzanfar,et al.  Estimating the Burden of Paratyphoid A in Asia and Africa , 2014, PLoS neglected tropical diseases.

[35]  A. Zaidi,et al.  A three year review of antimicrobial resistance of Salmonella enterica serovars Typhi and Paratyphi A in Pakistan , 2014 .

[36]  R. Black,et al.  Typhoid fever and paratyphoid fever: Systematic review to estimate global morbidity and mortality for 2010 , 2012, Journal of global health.

[37]  J. Clemens,et al.  Trends and disease burden of enteric fever in Guangxi province, China, 1994-2004. , 2010, Bulletin of the World Health Organization.

[38]  J. Crump,et al.  Global trends in typhoid and paratyphoid Fever. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  J. Wain,et al.  Salmonella Paratyphi A Rates, Asia , 2005, Emerging infectious diseases.

[40]  A. Pandey,et al.  Drug-resistant Salmonella enterica serotype paratyphi A in India. , 2000, Emerging infectious diseases.

[41]  Meeting of the Strategic Advisory Group of Experts on Immunization, November 2012 – conclusions and recommendations. , 2013, Releve epidemiologique hebdomadaire.

[42]  J. Andrews Determination of minimum inhibitory concentrations. , 2001, The Journal of antimicrobial chemotherapy.